Nuvectis Pharma, Inc.

NASDAQ:NVCT

Biotechnology

Healthcare
$20.29 +3.06%

+$0.39 today

Market cap
$697.75M
Beta
-0.07
P/E (TTM)
-11.2
EPS (TTM)
-$1.16
52W Low $5.55High $13.51

Volume 0.19M

Average 0.08M

NVCT Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Nuvectis Pharma, Inc.NASDAQ: NVCT

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows, but more slowly than its trailing trend

Q1 FY2026 selling, general & admin of $2.15M rose 14.1% year over year, behind the +36.8% change in trailing-twelve-month selling, general & admin. Sequentially, it fell 14.9% from the prior quarter. Over 3 fiscal years it compounded at +16.2% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether selling, general & admin reaches the consensus estimate from 5 analysts of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the +36.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.15M-14.9% QoQ
Last fiscal yearDec 2025
$9.42M+36.0% YoY
LTMMar 2026
$9.69M+36.8% YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+14.1%-100.0%-114.1 pp
1 year+36.0%-100.0%-136.0 pp
3-year CAGR+16.2%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

USD · from the income statement

Latest · FY2025
9.42M USD
Year-over-year change
+36.0%
4-year CAGR
+29.5%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How NVCT compares with its peers on the latest reported figures

  • NVCT's LTM Mar 2026 selling, general & admin of $9.69M is the lowest of the 11 companies compared; the peer median is $40.36M.
  • Its year-over-year change of +36.8% is the 3rd highest of 11, against a peer median of +19.7%.
  • Over three fiscal years its annual growth of +16.2% compares with a peer median of +18.2%.
NVCT Competitors Peer median
Selling, General & Admin for NVCT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMRXImmuneering CorporationLTM Mar 2026$4.7B +29505.3%+3.5%—
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$176.24M +26.9%+75.5%81.2%
NUVBNuvation Bio Inc.LTM Jun 2026$158.59M +32.6%+68.1%93.3%
VSTMVerastem, Inc.LTM Mar 2026$88.42M +83.1%+48.1%178.3%
JANXJanux Therapeutics, Inc.LTM Mar 2026$42.56M -1.1%+23.3%196.9%
MGNXMacroGenics, Inc.LTM Mar 2026$38.15M -27.9%-12.7%24.3%
ORICORIC Pharmaceuticals, Inc.LTM Mar 2026$33.29M +12.6%+9.8%—
MREOMereo BioPharma Group plcLTM Mar 2026$19.76M -28.1%-0.2%3951.0%
CMPXCompass Therapeutics, Inc.LTM Mar 2026$18.51M +10.2%+13.1%—
IMMXImmix Biopharma, Inc.LTM Mar 2026$15.81M +34.6%+50.4%—
NVCTNuvectis Pharma, Inc.LTM Mar 2026$9.69M +36.8%+16.2%—
Peer median (excluding NVCT) $40.36M+19.7%+18.2%135.8%

Competitors are the stored peer set for NVCT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00000
Gross Profit00000
Gross Margin—————
Research & Development9.55M13.23M15.38M12.92M18.15M
Selling, General & Admin3.35M6.01M7.52M6.93M9.42M
Operating Expenses12.89M19.23M22.9M19.85M27.57M
Depreciation & Amortization00000
EBITDA(12.89M)(19.09M)(22.26M)(19M)(26.44M)
EBITDA Margin—————
Operating Income(12.89M)(19.23M)(22.9M)(19.85M)(27.57M)
Operating Margin—————
Interest Income4K149K637K847K1.13M
Interest Expense00000
Other Income / Expenses4K149K637K847K1.13M
Income Before Tax(12.89M)(19.09M)(22.26M)(19M)(26.44M)
Pre-Tax Margin—————
Income Tax Expense00000
Net Income(12.89M)(19.09M)(22.26M)(19M)(26.44M)
Net Margin—————
EPS (Basic)(1.09)(1.51)(1.43)(1.11)(1.32)
EPS (Diluted)(1.09)(1.51)(1.43)(1.11)(1.32)
Weighted Avg Shares12.72M12.66M15.56M17.11M21.81M
Weighted Avg Shares (Diluted)12.72M12.66M15.56M17.11M21.81M

Nuvectis Pharma, Inc.

NASDAQ:NVCT

Intrinsic Alpha fair value

Locked

Current Price

$20.29

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.